Randall F. Holcombe, MD, Tisch Cancer Institute at Mount Sinai Medical Center, speaks about the use of aflibercept in patients with metastatic colorectal cancer.
Mount Sinai Tisch Cancer Center | Strategic Alliance Partners
Latest from Mount Sinai Tisch Cancer Center
William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses ongoing research into combination strategies for men with castration-resistant prostate cancer.
More potent versions of existing therapies are currently under development and showing considerable promise in early clinical trials for patients with multiple myeloma.
Over the past decade, the availability of new agents with varying mechanisms of action has greatly enhanced the treatment landscape in castration-resistant prostate cancer.
William K. Oh, MD, from the Tisch Cancer Institute, discusses strategies for sequencing the new therapies that have been approved for treating castration-resistant prostate cancer.
A whole-blood prognostic test based on gene-expression signatures may help predict risk for patients with castration-resistant prostate cancer.
Dr. Sundar Jagannath, from Mount Sinai Medical Center, Discusses the VANTAGE Trials
Dr. Marshall Posner, from Mount Sinai Medical Center, Discusses the Link Between HPV and Cancer
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
As ADC Options Expand, Sequencing and Toxicity Management Become the Next Challenges in Gynecologic Oncology
3
MANGROVE Trial Shows Improved Efficacy With Zanubrutinib Plus Rituximab vs Chemo in MCL
4
Experts Outline the Evolving Role of ctDNA-Based MRD Testing Across Solid Tumors
5